Beyond inducing weight loss, these treatments have demonstrated benefits on obesity-related complications, including neuropsychiatric and substance use disorders, peripheral vascular disease, arthritis, MASLD, hypertension and renal disorders, positioning them as a central focus in current obesity research [3]
RRR=relative risk reduction
Starting July 1, 2026, eligible Medicare Part D beneficiaries can access Wegovy for weight management through the Medicare GLP-1 Bridge at a $50 monthly copay
For anyone on semaglutide, being cautious with alcohol can help maximize the positive effects of the medication while minimizing potential problems
Unclear instructions Compounded medications can come with unclear instructions that are hard to follow